Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × melflufen × Plasma cell × Clear all

Phase

Phase 3 2 Phase 2 2 Phase 1/2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 1

Interventions

Dexamethasone 120 Lenalidomide 54 Bortezomib 48 Melphalan 43 Calcium Dobesilate 42 Cyclophosphamide 36 pomalidomide 33 carfilzomib 32 daratumumab 22 belantamab mafodotin 20 Peripheral Blood Stem Cell Transplantation 18 ixazomib 17 fludarabine 15 fludarabine phosphate 14 dexamethasone acetate 13 Bendamustine Hydrochloride 13 Whole-Body Irradiation 12 Filgrastim 12 Tacrolimus 11 Prednisone 11 selinexor 10 dexamethasone 21-phosphate 10 auricularum 10 Mycophenolic Acid 9 Cyclosporine 9 venetoclax 8 liposomal doxorubicin 8 iberdomide 8 Busulfan 8 pembrolizumab 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03481556 2022-12-19

ANCHOR

Oncopeptides AB

Phase 1/2 Terminated

56 enrolled 22 charts

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡